International Clinical Trials in Immunology/Infectious Diseases

Argentina

• Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
  Buenos Aires ; Research Site:
  
  
• Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
  La Plata; Research Site:
  
  
• Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
  Rosario; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Buenos Aires ; Research Site:
  
  
• HIV Infections: A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.
  Buenos Aires ; Research Site:
  
  
• HIV Infections: A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.
  Santa Fe; Research Site:
  
  
• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Buenos Aires ; Research Site:
  
  
• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Ciudad Autónoma De Bs. As.; Research Site:
  
  
• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Córdoba; Research Site:
  
  
• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Florida; Research Site:
  
  
• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Tucuman; Research Site:
  
  
• Pneumonia: A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia
  Buenos Aires ; Research Site:
  
  
• Pneumonia: A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia
  Ciudadela; Research Site:
  
  
• Pneumonia: A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia
  Córdoba; Research Site:
  
  
• Pneumonia: A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia
  Granadero Baigorria; Research Site:
  
  
• Pneumonia: A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia
  Parana; Research Site:
  
  
• Pneumonia: A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia
  Rosario; Research Site:
  
  
• Soft Tissue Infections: A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections
  Buenos Aires ; Research Site:
  
  
• Soft Tissue Infections: A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections
  Ciudadela; Research Site:
  
  
• Soft Tissue Infections: A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections
  Córdoba; Research Site:
  
  
• Soft Tissue Infections: A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections
  Granadero Baigorria; Research Site:
  
  
• Soft Tissue Infections: A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections
  Neuquen; Research Site:
  
  
• Soft Tissue Infections: A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections
  Palomar; Research Site:
  
  
• Soft Tissue Infections: A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections
  Parana; Research Site:
  
  
• Soft Tissue Infections: A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections
  Rosario; Research Site:
  
  
• Soft Tissue Infections: A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections
  Santa Fe; Research Site:
  
  
• Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus.
  Buenos Aires ; Research Site:
  
  
• Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus.
  Córdoba; Research Site:
  
  
• Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus.
  San Juan; Research Site:
  
  
• Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus.
  San Miguel De Tucuman; Research Site:
  
  
• Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus.
  Tucuman; Research Site:
  
  
• Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Systemic Lupus Erythematosus.
  Buenos Aires ; Research Site:
  
  
• Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Systemic Lupus Erythematosus.
  Córdoba; Research Site:
  
  
• Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Systemic Lupus Erythematosus.
  San Juan; Research Site:
  
  
• Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Systemic Lupus Erythematosus.
  San Miguel De Tucuman; Research Site:
  
  
• Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Systemic Lupus Erythematosus.
  Tucuman; Research Site:
  
  

Australia

• Cytomegalovirus Infections: A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients
  Parkville; Research Site:
  
  
• Cytomegalovirus Infections: IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
  Melbourne; Research Site:
  
  
• Cytomegalovirus Infections: IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
  Parkville; Research Site:
  
  
• Cytomegalovirus Infections: IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
  Sydney; Research Site:
  
  
• Cytomegalovirus Infections: VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients
  Chermside; Research Site:
  
  
• Cytomegalovirus Infections: VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients
  Darlinghurst; Research Site:
  
  
• Cytomegalovirus Infections: VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients
  Sydney; Research Site:
  
  
• Cytomegalovirus Infections: VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients
  Woolloongabba; Research Site:
  
  
• Hepatitis B: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
  Brisbane; Research Site:
  
  
• Hepatitis B: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
  Fitzroy; Research Site:
  
  
• Hepatitis C; Chronic: A Study of HCV Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.
  Adelaide; Research Site:
  
  
• Hepatitis C; Chronic: A Study of HCV Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.
  Brisbane; Research Site:
  
  
• Hepatitis C; Chronic: A Study of HCV Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.
  Melbourne; Research Site:
  
  
• Hepatitis C; Chronic: A Study of HCV Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.
  Sydney; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Administered Alone or in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Have Participated in Previous PEGASYS Trials.
  Adelaide; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Administered Alone or in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Have Participated in Previous PEGASYS Trials.
  Brisbane; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Administered Alone or in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Have Participated in Previous PEGASYS Trials.
  Melbourne; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Administered Alone or in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Have Participated in Previous PEGASYS Trials.
  Sydney; Research Site:
  
  
• Hepatitis C; Chronic: ACCELERATE Study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.
  Adelaide; Research Site:
  
  
• Hepatitis C; Chronic: ACCELERATE Study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.
  Brisbane; Research Site:
  
  
• Hepatitis C; Chronic: ACCELERATE Study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.
  Kingswood; Research Site:
  
  
• Hepatitis C; Chronic: ACCELERATE Study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.
  Melbourne; Research Site:
  
  
• Hepatitis C; Chronic: ACCELERATE Study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.
  Woolloongabba; Research Site:
  
  
• Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
  Adelaide; Research Site:
  
  
• Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
  Bankstown; Research Site:
  
  
• Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
  Box Hill; Research Site:
  
  
• Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
  Brisbane; Research Site:
  
  
• Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
  Cottontree; Research Site:
  
  
• Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
  Darlinghurst; Research Site:
  
  
• Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
  Douglas; Research Site:
  
  
• Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
  Fitzroy; Research Site:
  
  
• Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
  Fremantle; Research Site:
  
  
• Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
  Geelong; Research Site:
  
  
• Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
  Kingswood; Research Site:
  
  
• Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
  Lismore; Research Site:
  
  
• Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
  Liverpool; Research Site:
  
  
• Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
  Melbourne; Research Site:
  
  
• Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
  Miranda; Research Site:
  
  
• Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
  Nedlands; Research Site:
  
  
• Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
  New Lambton Heights; Research Site:
  
  
• Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
  Parkville; Research Site:
  
  
• Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
  Perth; Research Site:
  
  
• Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
  Sydney; Research Site:
  
  
• Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
  Victoria; Research Site:
  
  
• Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
  Woden; Research Site:
  
  
• Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
  Wollongong; Research Site:
  
  
• Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
  Woolloongabba; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Dee Why; Research Site:
  
  
• HIV Infections: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.
  Brisbane; Research Site:
  
  
• HIV Infections: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.
  Carlton; Research Site:
  
  
• HIV Infections: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.
  Liverpool; Research Site:
  
  
• HIV Infections: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.
  Melbourne; Research Site:
  
  
• HIV Infections: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.
  South Yarra; Research Site:
  
  
• HIV Infections: BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.
  Sydney; Research Site:
  
  
• HIV Infections: OPTIONS Study: A Study of Three Delivery Mechanisms for Fuzeon.
  Adelaide; Research Site:
  
  
• HIV Infections: OPTIONS Study: A Study of Three Delivery Mechanisms for Fuzeon.
  Brisbane; Research Site:
  
  
• HIV Infections: OPTIONS Study: A Study of Three Delivery Mechanisms for Fuzeon.
  Carlton; Research Site:
  
  
• HIV Infections: OPTIONS Study: A Study of Three Delivery Mechanisms for Fuzeon.
  Melbourne; Research Site:
  
  
• HIV Infections: OPTIONS Study: A Study of Three Delivery Mechanisms for Fuzeon.
  South Yarra; Research Site:
  
  
• HIV Infections: OPTIONS Study: A Study of Three Delivery Mechanisms for Fuzeon.
  Sydney; Research Site:
  
  
• HIV Infections: OPTIONS Study: A Study of Three Delivery Mechanisms for Fuzeon.
  Westmead; Research Site:
  
  
• Idiopathic Thrombocytopenic Purpura (ITP): A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
  Adelaide; Research Site:
  
  
• Idiopathic Thrombocytopenic Purpura (ITP): A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
  Frankston; Research Site:
  
  
• Idiopathic Thrombocytopenic Purpura (ITP): A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
  Gosford; Research Site:
  
  
• Idiopathic Thrombocytopenic Purpura (ITP): A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
  Malvern; Research Site:
  
  
• Idiopathic Thrombocytopenic Purpura (ITP): A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
  Melbourne; Research Site:
  
  
• Idiopathic Thrombocytopenic Purpura (ITP): A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
  Parkville; Research Site:
  
  
• Idiopathic Thrombocytopenic Purpura (ITP): A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
  Randwick; Research Site:
  
  
• Idiopathic Thrombocytopenic Purpura (ITP): A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
  Sydney; Research Site:
  
  
• Idiopathic Thrombocytopenic Purpura (ITP): A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
  Westmead; Research Site:
  
  
• Idiopathic Thrombocytopenic Purpura (ITP): A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
  Woolloongabba; Research Site:
  
  
• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Melbourne; Research Site:
  
  

Austria

• Cytomegalovirus Infections: A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation
  Innsbruck; Research Site:
  
  
• Cytomegalovirus Infections: A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation
  Wien; Research Site:
  
  
• Cytomegalovirus Infections: VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients
  Wien; Research Site:
  
  
• Hepatitis B: A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection
  Innsbruck; Research Site:
  
  
• Hepatitis B: A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection
  Vienna; Research Site:
  
  
• Hepatitis C; Chronic: A Study of HCV Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.
  Wien; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Administered Alone or in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Have Participated in Previous PEGASYS Trials.
  Wien; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
  Gratwein; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
  Graz; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
  Innsbruck; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
  Krems; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
  Linz; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
  Oberndorf; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
  Oberpullendorf; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
  Ried-Innkreis; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
  Salzburg; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
  Wels; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
  Wien; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
  Wiener Neustadt; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3
  Gratwein; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3
  Graz; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3
  Innsbruck; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3
  Krems; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3
  Linz; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3
  Oberndorf; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3
  Oberpullendorf; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3
  Ried-Innkreis; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3
  Salzburg; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3
  Villach; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3
  Vöcklabruck; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3
  Wels; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3
  Wien; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3
  Wiener Neustadt; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Wien; Research Site:
  
  
• Hepatitis C; Chronic: HELPS study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease
  Graz; Research Site:
  
  
• Hepatitis C; Chronic: HELPS study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease
  Wien; Research Site:
  
  

Bangladesh

• Hepatitis C; Chronic: A Study of Roferon-A (Interferon Alfa-2a) in Patients With Chronic Hepatitis C
  Dhaka; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Dhaka; Research Site:
  
  

Belgium

• Cytomegalovirus Infections: IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
  Bruxelles; Research Site:
  
  
• Cytomegalovirus Infections: IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
  Gent; Research Site:
  
  
• Cytomegalovirus Infections: IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
  Leuven; Research Site:
  
  
• Cytomegalovirus Infections: VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients
  Bruxelles; Research Site:
  
  
• Hepatitis C; Chronic: A Study of Combination Therapy With PEGASYS (Peginterferon alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response.
  Antwerpen; Research Site:
  
  
• Hepatitis C; Chronic: A Study of Combination Therapy With PEGASYS (Peginterferon alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response.
  Bruxelles; Research Site:
  
  
• Hepatitis C; Chronic: A Study of Combination Therapy With PEGASYS (Peginterferon alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response.
  Gent; Research Site:
  
  
• Hepatitis C; Chronic: A Study of Combination Therapy With PEGASYS (Peginterferon alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response.
  Kortrijk; Research Site:
  
  
• Hepatitis C; Chronic: A Study of Combination Therapy With PEGASYS (Peginterferon alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response.
  Liege; Research Site:
  
  
• Hepatitis C; Chronic: A Study of Induction Dosing With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C.
  Bruxelles; Research Site:
  
  
• Hepatitis C; Chronic: A Study of Induction Dosing With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C.
  Gent; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
  Antwerpen; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
  Assebroek; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
  Brugge; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
  Bruxelles; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
  Charleroi; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
  Edegem; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
  Genk; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
  Gent; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
  Gilly; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
  Haine-Saint-Paul; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
  Huy; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
  Kortrijk; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
  La Louviere; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
  Leuven; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
  Liege; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
  Mons; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
  Namur; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
  Roeselare; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
  Seraing; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
  Tournai; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
  Verviers; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
  Yvoir; Research Site:
  
  
• Hepatitis C; Chronic: A Study of Roferon-A (Interferon Alfa-2a) in Patients With Chronic Hepatitis C
  Bruxelles; Research Site:
  
  
• Hepatitis C; Chronic: BeTTy study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Combination Therapy in Patients With Chronic Hepatitis C (CHC)
  Bruxelles; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Bruxelles; Research Site:
  
  
• Hepatitis C; Chronic: PERFECT Study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC) and Human Immunodeficiency Virus (HIV) Co-infection, Not Responding to PEGASYS Plus Ribavirin
  Bruxelles; Research Site:
  
  
• Hepatitis C; Chronic: PERFECT Study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC) and Human Immunodeficiency Virus (HIV) Co-infection, Not Responding to PEGASYS Plus Ribavirin
  Charleroi; Research Site:
  
  
• Hepatitis C; Chronic: PERFECT Study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC) and Human Immunodeficiency Virus (HIV) Co-infection, Not Responding to PEGASYS Plus Ribavirin
  Edegem; Research Site:
  
  
• Hepatitis C; Chronic: PERFECT Study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC) and Human Immunodeficiency Virus (HIV) Co-infection, Not Responding to PEGASYS Plus Ribavirin
  Gent; Research Site:
  
  
• Hepatitis C; Chronic: PINGU study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Early Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1/4/5/6
  Antwerpen; Research Site:
  
  
• Hepatitis C; Chronic: PINGU study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Early Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1/4/5/6
  Brugge; Research Site:
  
  
• Hepatitis C; Chronic: PINGU study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Early Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1/4/5/6
  Bruxelles; Research Site:
  
  
• Hepatitis C; Chronic: PINGU study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Early Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1/4/5/6
  Charleroi; Research Site:
  
  
• Hepatitis C; Chronic: PINGU study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Early Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1/4/5/6
  Edegem; Research Site:
  
  
• Hepatitis C; Chronic: PINGU study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Early Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1/4/5/6
  Gent; Research Site:
  
  
• Hepatitis C; Chronic: PINGU study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Early Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1/4/5/6
  Liege; Research Site:
  
  
• Hepatitis C; Chronic: PINGU study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Early Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1/4/5/6
  Namur; Research Site:
  
  
• Hepatitis C; Chronic: PINGU study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Early Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1/4/5/6
  Yvoir; Research Site:
  
  
• Hepatitis C; Chronic: REPEAT study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon alfa-2b (12KD))/Ribavirin Combination Therapy
  Leuven; Research Site:
  
  
• Hepatitis C; Chronic: REPEAT study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon alfa-2b (12KD))/Ribavirin Combination Therapy
  Gent; Research Site:
  
  
• Hepatitis C; Chronic: REPEAT study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon alfa-2b (12KD))/Ribavirin Combination Therapy
  Bruxelles; Research Site:
  
  
• HIV Infections: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
  Zaventem; Research Site:
  
  
• HIV Infections: A Study to Evaluate the Safety and Tolerability of Fuzeon (Enfuvirtide) in Combination With Antiretroviral Agents in Patients With Advanced Human Immunodeficiency Virus (HIV) Infection, Unable to Construct a Viable Treatment Regimen
  Bruxelles; Research Site:
  
  
• Influenza: A Study of Tamiflu (Oseltamivir) for the Seasonal Prophylaxis of Influenza in Immunocompromised Patients.
  Aalst; Research Site:
  
  
• Influenza: A Study of Tamiflu (Oseltamivir) for the Seasonal Prophylaxis of Influenza in Immunocompromised Patients.
  Bruxelles; Research Site:
  
  
• Influenza: A Study of Tamiflu (Oseltamivir) for the Seasonal Prophylaxis of Influenza in Immunocompromised Patients.
  Edegem; Research Site:
  
  
• Influenza: A Study of Tamiflu (Oseltamivir) for the Seasonal Prophylaxis of Influenza in Immunocompromised Patients.
  Leuven; Research Site:
  
  
• Influenza: A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
  Aalst; Research Site:
  
  
• Influenza: A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
  Bruxelles; Research Site:
  
  
• Influenza: A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
  Leuven; Research Site:
  
  
• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Bruxelles; Research Site:
  
  

Bosnia and Herzegovina

• Hepatitis C; Chronic: CEE study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) and COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC)
  Sarajevo; Research Site:
  
  

Brazil

• Atopic Dermatitis: A Study of Protopic (Tacrolimus) Ointment in Children With Atopic Dermatitis
  Belo Horizonte; Research Site:
  
  
• Atopic Dermatitis: A Study of Protopic (Tacrolimus) Ointment in Children With Atopic Dermatitis
  Guarulhos; Research Site:
  
  
• Atopic Dermatitis: A Study of Protopic (Tacrolimus) Ointment in Children With Atopic Dermatitis
  Porto Alegre; Research Site:
  
  
• Atopic Dermatitis: A Study of Protopic (Tacrolimus) Ointment in Children With Atopic Dermatitis
  Sao Paulo; Research Site:
  
  
• Cytomegalovirus Infections: IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
  Campinas; Research Site:
  
  
• Cytomegalovirus Infections: IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
  Porto Alegre; Research Site:
  
  
• Cytomegalovirus Infections: IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
  Sao Paulo; Research Site:
  
  
• Cytomegalovirus Infections: VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients
  Campinas; Research Site:
  
  
• Cytomegalovirus Infections: VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients
  Porto Alegre; Research Site:
  
  
• Cytomegalovirus Infections: VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients
  Sao Paulo; Research Site:
  
  
• Hepatitis B: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
  Campinas; Research Site:
  
  
• Hepatitis B: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
  Ribeirão Preto; Research Site:
  
  
• Hepatitis B: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
  Salvador; Research Site:
  
  
• Hepatitis B: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
  Santo Andre; Research Site:
  
  
• Hepatitis B: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
  Sao Paulo; Research Site:
  
  
• Hepatitis C; Chronic: A Study of Combination Therapy With PEGASYS (Peginterferon alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response.
  Brasilia; Research Site:
  
  
• Hepatitis C; Chronic: A Study of Combination Therapy With PEGASYS (Peginterferon alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response.
  Campinas; Research Site:
  
  
• Hepatitis C; Chronic: A Study of Combination Therapy With PEGASYS (Peginterferon alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response.
  Porto Alegre; Research Site:
  
  
• Hepatitis C; Chronic: A Study of Combination Therapy With PEGASYS (Peginterferon alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response.
  Rio De Janeiro; Research Site:
  
  
• Hepatitis C; Chronic: A Study of Combination Therapy With PEGASYS (Peginterferon alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response.
  Sao Luis; Research Site:
  
  
• Hepatitis C; Chronic: A Study of Combination Therapy With PEGASYS (Peginterferon alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response.
  Sao Paulo; Research Site:
  
  
• Hepatitis C; Chronic: A Study of Combination Therapy With PEGASYS (Peginterferon alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response.
  Sorocaba; Research Site:
  
  
• Hepatitis C; Chronic: A Study of Combination Therapy With PEGASYS (Peginterferon alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response.
  Vitoria; Research Site:
  
  
• Hepatitis C; Chronic: A Study of Induction Dosing With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C.
  Caixa; Research Site:
  
  
• Hepatitis C; Chronic: A Study of Induction Dosing With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C.
  Campinas; Research Site:
  
  
• Hepatitis C; Chronic: A Study of Induction Dosing With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C.
  Juiz De Fora; Research Site:
  
  
• Hepatitis C; Chronic: A Study of Induction Dosing With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C.
  Porto Alegre; Research Site:
  
  
• Hepatitis C; Chronic: A Study of Induction Dosing With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C.
  Salvador; Research Site:
  
  
• Hepatitis C; Chronic: A Study of Induction Dosing With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C.
  Sao Jose do Rio Preto; Research Site:
  
  
• Hepatitis C; Chronic: A Study of Induction Dosing With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C.
  Sao Paulo; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Administered Alone or in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Have Participated in Previous PEGASYS Trials.
  Ribeirão Preto; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Administered Alone or in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Have Participated in Previous PEGASYS Trials.
  Salvador; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Administered Alone or in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Have Participated in Previous PEGASYS Trials.
  Sao Paulo; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) and COPEGUS (Ribavirin) Combination Therapy in Patients With Chronic Hepatitis C (CHC) and Various Degrees of Renal Impairment.
  Sao Paulo; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) plus Ribavirin, With or Without Amantidine, in Non-Responding or Relapsing Patients With Chronic Hepatitis C (CHC)
  Belo Horizonte; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) plus Ribavirin, With or Without Amantidine, in Non-Responding or Relapsing Patients With Chronic Hepatitis C (CHC)
  Botucatu; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) plus Ribavirin, With or Without Amantidine, in Non-Responding or Relapsing Patients With Chronic Hepatitis C (CHC)
  Campinas; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) plus Ribavirin, With or Without Amantidine, in Non-Responding or Relapsing Patients With Chronic Hepatitis C (CHC)
  Curitiba; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) plus Ribavirin, With or Without Amantidine, in Non-Responding or Relapsing Patients With Chronic Hepatitis C (CHC)
  Goiania; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) plus Ribavirin, With or Without Amantidine, in Non-Responding or Relapsing Patients With Chronic Hepatitis C (CHC)
  Porto Alegre; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) plus Ribavirin, With or Without Amantidine, in Non-Responding or Relapsing Patients With Chronic Hepatitis C (CHC)
  Recife; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) plus Ribavirin, With or Without Amantidine, in Non-Responding or Relapsing Patients With Chronic Hepatitis C (CHC)
  Salvador; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) plus Ribavirin, With or Without Amantidine, in Non-Responding or Relapsing Patients With Chronic Hepatitis C (CHC)
  Sao Paulo; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a(40KD)) plus Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection.
  Campinas; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a(40KD)) plus Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection.
  Florianopolis; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a(40KD)) plus Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection.
  Itajaí; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a(40KD)) plus Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection.
  Juiz De Fora; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a(40KD)) plus Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection.
  Porto Alegre; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a(40KD)) plus Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection.
  Recife; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a(40KD)) plus Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection.
  Ribeirão Preto; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a(40KD)) plus Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection.
  Rio De Janeiro; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a(40KD)) plus Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection.
  Rio Grande; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a(40KD)) plus Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection.
  Santo Andre; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a(40KD)) plus Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection.
  Santos; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a(40KD)) plus Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection.
  Sao Paulo; Research Site:
  
  
• Hepatitis C; Chronic: A Study of Roferon-A (Interferon Alfa-2a) in Patients With Chronic Hepatitis C
  Botucatu; Research Site:
  
  
• Hepatitis C; Chronic: A Study of Roferon-A (Interferon Alfa-2a) in Patients With Chronic Hepatitis C
  Curitiba; Research Site:
  
  
• Hepatitis C; Chronic: A Study of Roferon-A (Interferon Alfa-2a) in Patients With Chronic Hepatitis C
  Porto Alegre; Research Site:
  
  
• Hepatitis C; Chronic: A Study of Roferon-A (Interferon Alfa-2a) in Patients With Chronic Hepatitis C
  Recife; Research Site:
  
  
• Hepatitis C; Chronic: A Study of Roferon-A (Interferon Alfa-2a) in Patients With Chronic Hepatitis C
  Vitoria; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Sao Paulo; Research Site:
  
  
• Hepatitis C; Chronic: HELPS study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease
  Brasilia; Research Site:
  
  
• Hepatitis C; Chronic: HELPS study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease
  Porto Alegre; Research Site:
  
  
• Hepatitis C; Chronic: HELPS study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease
  Sao Jose do Rio Preto; Research Site:
  
  
• Hepatitis C; Chronic: HELPS study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease
  Sao Luis; Research Site:
  
  
• Hepatitis C; Chronic: HELPS study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease
  Sao Paulo; Research Site:
  
  
• Hepatitis C; Chronic: POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin).
  Campinas; Research Site:
  
  
• Hepatitis C; Chronic: POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin).
  Porto Alegre; Research Site:
  
  
• Hepatitis C; Chronic: POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin).
  Sao Luis; Research Site:
  
  
• Hepatitis C; Chronic: POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin).
  Sao Paulo; Research Site:
  
  
• Hepatitis C; Chronic: POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin).
  Sorocaba; Research Site:
  
  
• Hepatitis C; Chronic: REPEAT study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon alfa-2b (12KD))/Ribavirin Combination Therapy
  Rio De Janeiro; Research Site:
  
  
• HIV Infections: A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.
  Belo Horizonte; Research Site:
  
  
• HIV Infections: A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.
  Nova Iguaçu; Research Site:
  
  
• HIV Infections: A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.
  Porto Alegre; Research Site:
  
  
• HIV Infections: A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.
  Ribeirão Preto; Research Site:
  
  
• HIV Infections: A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.
  Salvador; Research Site:
  
  
• HIV Infections: A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.
  Sao Paulo; Research Site:
  
  
• HIV Infections: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
  Campinas; Research Site:
  
  
• HIV Infections: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
  Porto Alegre; Research Site:
  
  
• HIV Infections: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
  Rio De Janeiro; Research Site:
  
  
• HIV Infections: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
  Salvador; Research Site:
  
  
• HIV Infections: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
  Sao Paulo; Research Site:
  
  
• HIV Infections: A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon
  Campinas; Research Site:
  
  
• HIV Infections: A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon
  Porto Alegre; Research Site:
  
  
• HIV Infections: A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon
  Rio De Janeiro; Research Site:
  
  
• HIV Infections: A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon
  Salvador; Research Site:
  
  
• HIV Infections: A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon
  Sao Paulo; Research Site:
  
  
• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Rio De Janeiro; Research Site:
  
  
• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Sao Paulo; Research Site:
  
  
• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Sorocaba; Research Site:
  
  
• Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus.
  Belo Horizonte; Research Site:
  
  
• Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus.
  Brasilia; Research Site:
  
  
• Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus.
  Curitiba; Research Site:
  
  
• Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus.
  Fortaleza; Research Site:
  
  
• Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus.
  Goiania; Research Site:
  
  
• Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus.
  Marilia; Research Site:
  
  
• Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus.
  Porto Alegre; Research Site:
  
  
• Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus.
  Recife; Research Site:
  
  
• Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus.
  Ribeirão Preto; Research Site:
  
  
• Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus.
  Rio De Janeiro; Research Site:
  
  
• Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus.
  Sao Paulo; Research Site:
  
  
• Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Systemic Lupus Erythematosus.
  Belo Horizonte; Research Site:
  
  
• Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Systemic Lupus Erythematosus.
  Brasilia; Research Site:
  
  
• Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Systemic Lupus Erythematosus.
  Curitiba; Research Site:
  
  
• Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Systemic Lupus Erythematosus.
  Fortaleza; Research Site:
  
  
• Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Systemic Lupus Erythematosus.
  Goiania; Research Site:
  
  
• Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Systemic Lupus Erythematosus.
  Porto Alegre; Research Site:
  
  
• Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Systemic Lupus Erythematosus.
  Recife; Research Site:
  
  
• Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Systemic Lupus Erythematosus.
  Ribeirão Preto; Research Site:
  
  
• Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Systemic Lupus Erythematosus.
  Rio De Janeiro; Research Site:
  
  
• Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Systemic Lupus Erythematosus.
  Sao Paulo; Research Site:
  
  

Bulgaria

• Hepatitis B: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
  Pleven; Research Site:
  
  
• Hepatitis B: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
  Plovdiv; Research Site:
  
  
• Hepatitis B: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
  Sofia; Research Site:
  
  
• Hepatitis B: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
  Stara Zagora; Research Site:
  
  
• Hepatitis B: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
  Varna; Research Site:
  
  
• Hepatitis B: SOFIA-LTT Study: A Study of Intermittent Long Term Treatment With PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Negative Chronic Hepatitis B (CHB).
  Sofia; Research Site:
  
  
• Hepatitis C; Chronic: A Study of Roferon-A (Interferon Alfa-2a) in Patients With Chronic Hepatitis C
  Sofia; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Sofia; Research Site:
  
  
• HIV Infections: A Study of Fuzeon (Enfuvirtide) in Patients With Advanced Human Immunodeficiency Virus-1 (HIV-1) Infection
  Sofia; Research Site:
  
  
• Influenza: A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
  Plovdiv; Research Site:
  
  
• Influenza: A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
  Sofia; Research Site:
  
  
• Pneumonia: A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia
  Ruse; Research Site:
  
  
• Pneumonia: A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia
  Sofia; Research Site:
  
  
• Soft Tissue Infections: A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections
  Pleven; Research Site:
  
  
• Soft Tissue Infections: A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections
  Plovdiv; Research Site:
  
  
• Soft Tissue Infections: A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections
  Sofia; Research Site:
  
  
• Soft Tissue Infections: A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections
  Varna; Research Site:
  
  
• Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus.
  Pleven; Research Site:
  
  
• Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus.
  Sofia; Research Site:
  
  
• Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Systemic Lupus Erythematosus.
  Pleven; Research Site:
  
  
• Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Systemic Lupus Erythematosus.
  Sofia; Research Site:
  
  

Canada

• Allergy: A Safety and Efficacy Study of Xolair in Peanut Allergy
  Ontario; Research Site
  
  
• Allergy: A Safety and Efficacy Study of Xolair in Peanut Allergy
  Quebec; Research Site
  
  
• Celiac Disease: A Dose Ranging Study to Determine the Safety, Tolerance, and Efficacy of an Investigational Drug AT-1001 in Celiac Disease Subjects during a Gluten Challenge
  Calgary, AR; Research Site
  
  
• Celiac Disease: A Dose Ranging Study to Determine the Safety, Tolerance, and Efficacy of an Investigational Drug AT-1001 in Celiac Disease Subjects during a Gluten Challenge
  Edmonton, AB; Research Site
  
  
• Celiac Disease: A Dose Ranging Study to Determine the Safety, Tolerance, and Efficacy of an Investigational Drug AT-1001 in Celiac Disease Subjects during a Gluten Challenge
  Kelowna, BC; Research Site
  
  
• Celiac Disease: A Dose Ranging Study to Determine the Safety, Tolerance, and Efficacy of an Investigational Drug AT-1001 in Celiac Disease Subjects during a Gluten Challenge
  Montreal, QC; Research Site
  
  
• Celiac Disease: A Dose Ranging Study to Determine the Safety, Tolerance, and Efficacy of an Investigational Drug AT-1001 in Celiac Disease Subjects during a Gluten Challenge
  Toronto, ON; Research Site
  
  
• Celiac Disease: A Dose Ranging Study to Determine the Safety, Tolerance, and Efficacy of an Investigational Drug AT-1001 in Celiac Disease Subjects during a Gluten Challenge
  Winnipeg, MB; Research Site
  
  
• Cytomegalovirus Infections: A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients
  Edmonton, AB; Research Site:
  
  
• Cytomegalovirus Infections: A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients
  Winnipeg, MB; Research Site:
  
  
• Cytomegalovirus Infections: IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
  Edmonton, AB; Research Site:
  
  
• Cytomegalovirus Infections: IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
  Hamilton, ON; Research Site:
  
  
• Cytomegalovirus Infections: IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
  Montreal, QC; Research Site:
  
  
• Cytomegalovirus Infections: IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
  Toronto, ON; Research Site:
  
  
• Cytomegalovirus Infections: VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients
  Edmonton, AB; Research Site:
  
  
• Cytomegalovirus Infections: VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients
  Toronto, ON; Research Site:
  
  
• Hepatitis C; Chronic: A Study of HCV Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.
  Calgary, AB; Research Site:
  
  
• Hepatitis C; Chronic: A Study of HCV Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.
  Ottawa, ON; Research Site:
  
  
• Hepatitis C; Chronic: A Study of HCV Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.
  Toronto, ON; Research Site:
  
  
• Hepatitis C; Chronic: A Study of HCV Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.
  Vancouver, BC; Research Site:
  
  
• Hepatitis C; Chronic: A Study of Induction Dosing With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C.
  Edmonton, AB; Research Site:
  
  
• Hepatitis C; Chronic: A Study of Induction Dosing With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C.
  Halifax, NS; Research Site:
  
  
• Hepatitis C; Chronic: A Study of Induction Dosing With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C.
  London, ON; Research Site:
  
  
• Hepatitis C; Chronic: A Study of Induction Dosing With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C.
  Ottawa, ON; Research Site:
  
  
• Hepatitis C; Chronic: A Study of Induction Dosing With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C.
  Toronto, ON; Research Site:
  
  
• Hepatitis C; Chronic: A Study of Induction Dosing With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C.
  Vancouver, BC; Research Site:
  
  
• Hepatitis C; Chronic: A Study of Induction Dosing With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C.
  Winnipeg, MB; Research Site:
  
  
• Hepatitis C; Chronic: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) plus Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection, With and Without Highly Active Antiretroviral Therapy (HAART)
  Edmonton, AB; Research Site:
  
  
• Hepatitis C; Chronic: ACCELERATE Study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.
  Downsview, ON; Research Site:
  
  
• Hepatitis C; Chronic: ACCELERATE Study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.
  Edmonton, AB; Research Site:
  
  
• Hepatitis C; Chronic: ACCELERATE Study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.
  Mississauga, ON; Research Site:
  
  
• Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
  Abbotsford, BC; Research Site:
  
  
• Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
  Barrie, ON; Research Site:
  
  
• Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
  Brampton, ON; Research Site:
  
  
• Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
  Calgary, AB; Research Site:
  
  
• Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
  Downsview, ON; Research Site:
  
  
• Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
  Edmonton, AB; Research Site:
  
  
• Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
  Hamilton, ON; Research Site:
  
  
• Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
  Kingston, ON; Research Site:
  
  
• Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
  London, ON; Research Site:
  
  
• Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
  Mississauga, ON; Research Site:
  
  
• Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
  Montreal, QC; Research Site:
  
  
• Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
  Newmarket, ON; Research Site:
  
  
• Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
  Oshawa, ON; Research Site:
  
  
• Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
  Ottawa, ON; Research Site:
  
  
• Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
  Quebec City, QC; Research Site:
  
  
• Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
  Regina, SK; Research Site:
  
  
• Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
  Richmond Hill, ON; Research Site:
  
  
• Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
  St-Charles Borromee, QC; Research Site:
  
  
• Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
  Sudbury, ON; Research Site:
  
  
• Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
  Surrey, BC; Research Site:
  
  
• Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
  Thunder Bay, ON; Research Site:
  
  
• Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
  Toronto, ON; Research Site:
  
  
• Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
  Vancouver, BC; Research Site:
  
  
• Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
  Vernon, BC; Research Site:
  
  
• Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
  West Vancouver, BC; Research Site:
  
  
• Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
  Whitby, ON; Research Site:
  
  
• Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
  Windsor, ON; Research Site:
  
  
• Hepatitis C; Chronic: APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
  Winnipeg, MB; Research Site:
  
  
• Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
  Calgary, AB; Research Site:
  
  
• Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
  Edmonton, AB; Research Site:
  
  
• Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
  Mississauga, ON; Research Site:
  
  
• Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
  Montreal, QC; Research Site:
  
  
• Hepatitis C; Chronic: CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
  Vancouver, BC; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Abbotsford, BC; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Barrie, ON; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Brampton, ON; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Calgary, AB; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Downsview, ON; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Edmonton, AB; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Etobicoke, ON; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Guelph, ON; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Halifax, NS; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Hamilton, ON; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Hunstville; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Kingston, ON; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  London, ON; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Mississauga, ON; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Moncton, NB; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Montreal, QC; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Nelson, BC; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  New Westminster, BC; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Newmarket, ON; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  North Vancouver, BC; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Oshawa, ON; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Ottawa, ON; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Pickering, ON; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Red Deer, AB; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Regina, SK; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Saskatoon, SK; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Scarborough, ON; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  St John'S; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Summerside, PE; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Surrey, BC; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Thornhill, ON; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Thunder Bay, ON; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Toronto, ON; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Vancouver, BC; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Vancouver, ON; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Vernon, BC; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Victoria, BC; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Westmount, QC; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Windsor, ON; Research Site:
  
  
• Hepatitis C; Chronic: EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
  Winnipeg, MB; Research Site:
  
  
• Hepatitis C; Chronic: IMPROVE Study(The Individualized Management with PEGASYS and Ribavirin Offering Viral Eradication): A Study of PEGASYS® (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Non-Genotype 2/3.
  Mississauga, ON; Research Site:
  
  
• Hepatitis C; Chronic: IMPROVE Study(The Individualized Management with PEGASYS and Ribavirin Offering Viral Eradication): A Study of PEGASYS® (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Non-Genotype 2/3.
  Toronto, ON; Research Site:
  
  
• Hepatitis C; Chronic: IMPROVE Study(The Individualized Management with PEGASYS and Ribavirin Offering Viral Eradication): A Study of PEGASYS® (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Non-Genotype 2/3.
  London, ON; Research Site:
  
  
• Hepatitis C; Chronic: IMPROVE Study(The Individualized Management with PEGASYS and Ribavirin Offering Viral Eradication): A Study of PEGASYS® (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Non-Genotype 2/3.
  Abbotsford, BC; Research Site:
  
  
• Hepatitis C; Chronic: IMPROVE Study(The Individualized Management with PEGASYS and Ribavirin Offering Viral Eradication): A Study of PEGASYS® (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Non-Genotype 2/3.
  Halifax, NS; Research Site:
  
  
• Hepatitis C; Chronic: IMPROVE Study(The Individualized Management with PEGASYS and Ribavirin Offering Viral Eradication): A Study of PEGASYS® (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Non-Genotype 2/3.
  Vancouver, BC; Research Site:
  
  
• Hepatitis C; Chronic: IMPROVE Study(The Individualized Management with PEGASYS and Ribavirin Offering Viral Eradication): A Study of PEGASYS® (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Non-Genotype 2/3.
  Vernon, BC; Research Site:
  
  
• Hepatitis C; Chronic: IMPROVE Study(The Individualized Management with PEGASYS and Ribavirin Offering Viral Eradication): A Study of PEGASYS® (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Non-Genotype 2/3.
  Calgary, AB; Research Site:
  
  
• Hepatitis C; Chronic: IMPROVE Study(The Individualized Management with PEGASYS and Ribavirin Offering Viral Eradication): A Study of PEGASYS® (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Non-Genotype 2/3.
  Victoria, BC; Research Site:
  
  
• Hepatitis C; Chronic: IMPROVE Study(The Individualized Management with PEGASYS and Ribavirin Offering Viral Eradication): A Study of PEGASYS® (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Non-Genotype 2/3.
  Hamilton, ON; Research Site:
  
  
• Hepatitis C; Chronic: IMPROVE Study(The Individualized Management with PEGASYS and Ribavirin Offering Viral Eradication): A Study of PEGASYS® (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Non-Genotype 2/3.
  Montreal, QC; Research Site:
  
  
• Hepatitis C; Chronic: IMPROVE Study(The Individualized Management with PEGASYS and Ribavirin Offering Viral Eradication): A Study of PEGASYS® (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Non-Genotype 2/3.
  Edmonton, AB; Research Site:
  
  
• Hepatitis C; Chronic: IMPROVE Study(The Individualized Management with PEGASYS and Ribavirin Offering Viral Eradication): A Study of PEGASYS® (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Non-Genotype 2/3.
  Ottawa, ON; Research Site:
  
  
• Hepatitis C; Chronic: IMPROVE Study(The Individualized Management with PEGASYS and Ribavirin Offering Viral Eradication): A Study of PEGASYS® (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Non-Genotype 2/3.
  Saskatoon, SK; Research Site:
  
  
• Hepatitis C; Chronic: IMPROVE Study(The Individualized Management with PEGASYS and Ribavirin Offering Viral Eradication): A Study of PEGASYS® (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Non-Genotype 2/3.
  Kingston, ON; Research Site:
  
  
• Hepatitis C; Chronic: REPEAT study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon alfa-2b (12KD))/Ribavirin Combination Therapy
  Vancouver, BC; Research Site:
  
  
• Hepatitis C; Chronic: REPEAT study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon alfa-2b (12KD))/Ribavirin Combination Therapy
  Toronto, ON; Research Site:
  
  
• HIV Infections: A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients
  Montreal, QC; Research Site:
  
  
• HIV Infections: A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients
  Toronto, ON; Research Site:
  
  
• HIV Infections: A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection.
  Ottawa, ON; Research Site:
  
  
• HIV Infections: A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection.
  Toronto, ON; Research Site:
  
  
• HIV Infections: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
  Calgary, AB; Research Site:
  
  
• HIV Infections: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
  Edmonton, AB; Research Site:
  
  
• HIV Infections: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
  Halifax, NS; Research Site:
  
  
• HIV Infections: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
  Montreal, QC; Research Site:
  
  
• HIV Infections: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
  Ottawa, ON; Research Site:
  
  
• HIV Infections: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
  Saskatoon, SK; Research Site:
  
  
• HIV Infections: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
  Toronto, ON; Research Site:
  
  
• HIV Infections: A Study to Assess the Safety of Fuzeon (Enfuvirtide) in Combination with Oral Antiretroviral Agents in Patients with Advanced Human Immunodeficiency Virus (HIV) Disease, Unable to Construct a Viable Treatment Regimen
  Vancouver, BC; Research Site:
  
  
• HIV Infections: A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon
  Calgary, AB; Research Site:
  
  
• HIV Infections: A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon
  Edmonton, AB; Research Site:
  
  
• HIV Infections: A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon
  Hamilton, ON; Research Site:
  
  
• HIV Infections: A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon
  Montreal, QC; Research Site:
  
  
• HIV Infections: A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon
  Ottawa, ON; Research Site:
  
  
• HIV Infections: A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon
  Saskatoon, SK; Research Site:
  
  
• HIV Infections: A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon
  Toronto, ON; Research Site:
  
  
• HIV Infections: A Study to Collect Safety Data for Fuzeon (Enfuvirtide) in Patients With Human Immunodeficiency Virus (HIV) Infection Who Have Participated in Prior Clinical Studies of Fuzeon
  Vancouver, BC; Research Site:
  
  
• HIV Infections: A Study to Evaluate the Safety and Efficacy of Switching Human Immunodeficiency Virus (HIV)-infected Patients From a Toxicity-Causing Antiretroviral (ARV) Agent to Fuzeon
  Montreal, QC; Research Site:
  
  
• HIV Infections: GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection
  Hamilton, ON; Research Site:
  
  
• HIV Infections: GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection
  Montreal, QC; Research Site:
  
  
• HIV Infections: GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection
  Ottawa, ON; Research Site:
  
  
• HIV Infections: GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection
  Toronto, ON; Research Site:
  
  
• Influenza: A Study of Tamiflu (Oseltamivir) for Seasonal Prophylaxis of Influenza in Children.
  Coquitlam, BC; Research Site:
  
  
• Influenza: A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
  Saskatoon, SK; Research Site:
  
  
• Influenza: A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.
  Winnipeg, MB; Research Site:
  
  
• Lupus: A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis.
  Montreal, QC; Research Site:
  
  
• Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus.
  Scarborough, ON; Research Site:
  
  
• Systemic Lupus Erythematosus: A Study of Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus.
  Toronto, ON; Research Site:
  
  
• Systemic Lupus Erythematosus: A Study of Ocrel